Article
Boston-SOLX, the glaucoma division of OccuLogix Inc., has begun an international program to train and certify ophthalmologists in Europe and the Middle East in surgical implantation procedures using the company's Gold Micro-Shunt products.
Boston-SOLX, the glaucoma division of OccuLogix Inc., has begun an international program to train and certify ophthalmologists in Europe and the Middle East in surgical implantation procedures using the company's Gold Micro-Shunt products.
Surgical certification is conducted at individual surgery practices, and didactic training sessions are being offered globally at various locations (see http://www.solx.com/).
The products were launched in September. FDA clinical studies are under way at 10 centers worldwide.
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial